Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial (VICTORY)
A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery in Diabetic Patients
Sponsor: GlaxoSmithKline
Listed as NCT00169832, this PHASE3 trial focuses on Coronary Artery Bypass Grafting and Diabetes and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Laval University
For direct contact, visit the study record on ClinicalTrials.gov .